A375 (ATCC® CCL-121™) is a human melanoma cell line initiated through explant culture of a solid tumor from a 54-year-old female. The cells are adherent with an epithelial morphology. The cells form tumors following implantation into immunocompromised mice.
A375 cells are suitable for in vitro and in vivo experimentation. Immunocompromised mice should be used for in life studies, and will form tumors following implantation of the cells.
The following chart provides some examples of A375 cells used as a xenograft model.
|Route of Implantation||Mice||Tumor/Metastases||References|
|Intradermal||NOD/SCID||Dermal tumors, micrometastases in lung and brain||
Rozenberg et al. (2010) Melanoma Res 20:361-371.
White et al. (2009) Purinergic Signal 5: 327-333.
|Tail vein||NSG||Lung metastases||
Weber et al. (2016) Cancer Res 15: 3562-3571.
|Intracardiac||Nude||Lung, liver, bone, and lymph node metastases||
Huang et al. (2014) Endocrinology 155:3739-3749.
Stable reporter cell lines:
Our A375 reporter cell lines can be tracked in vivo, making them great tools for studying the mechanisms of tumor growth and metastasis, as well as evaluating the effects of various drugs or therapies in animals. Our A375 cells are available with a variety of different reporters, including the human sodium iodide symporter (hNIS), firefly luciferase (Fluc), enhanced green fluorescent protein (eGFP), or near-infrared fluorescent protein (iRFP). Several dual reporter A375 cell lines are available to facilitate multi-modality imaging.
In order to ensure high, constitutive expression of the reporter proteins, our cell lines are generated by lentivirus transduction. The lentivirus vectors used for these transductions are self-inactivating (SIN) vectors in which the viral enhancer and promoter has been deleted. This increases the biosafety of the lentiviruses by preventing mobilization of replication competent viruses (Miyoshi et al., J Virol. 1998).